Levodopa‐induced hyperactivity in mice treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine
Identifieur interne : 001861 ( Istex/Corpus ); précédent : 001860; suivant : 001862Levodopa‐induced hyperactivity in mice treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine
Auteurs : Anthony P. NicholasSource :
- Movement Disorders [ 0885-3185 ] ; 2007-01.
English descriptors
- KwdEn :
Abstract
The present study examines the motor responses of 10‐ to 12‐month‐old, male C57 mice that were either given intraperitoneal (IP) injections of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP; 30 mg/kg per day) or vehicle for 10 consecutive days, followed by IP injections of levodopa (200 mg/kg) plus carbidopa (25 mg/kg). Five days of MPTP exposure resulted in the Straub tail phenomenon and pronounced hypokinesia. However, during the next 5 days, motor activity returned to baseline, even with continued MPTP treatment. After 10 to 14 days of rest, all mice were then treated with levodopa/carbidopa twice daily for multiple, consecutive days. However, only the previously MPTP‐treated animals became hyperkinetic, as compared to levodopa‐treated control animals that were not previously exposed to MPTP. Abnormal activity included scratching, running, gnawing, and jumping movements. Hyperactivity lasted for approximately 2 hours after each levodopa injection and then returned to baseline, but the amount of hyperkinesia increased with additional days of levodopa treatment, even though the daily levodopa dose was not changed. These results demonstrate that levodopa can cause reproducible hyperactivity in mice that were previously exposed to MPTP. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21235
Links to Exploration step
ISTEX:62C0B2743415A52B75D6196C907163F70060A5DFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa‐induced hyperactivity in mice treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine</title><author><name sortKey="Nicholas, Anthony P" sort="Nicholas, Anthony P" uniqKey="Nicholas A" first="Anthony P." last="Nicholas">Anthony P. Nicholas</name><affiliation><mods:affiliation>Department of Neurology, University of Alabama at Birmingham and the Birmingham Veterans Administration Medical Center, Birmingham, Alabama, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:62C0B2743415A52B75D6196C907163F70060A5DF</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21235</idno><idno type="url">https://api.istex.fr/document/62C0B2743415A52B75D6196C907163F70060A5DF/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001861</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa‐induced hyperactivity in mice treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine</title><author><name sortKey="Nicholas, Anthony P" sort="Nicholas, Anthony P" uniqKey="Nicholas A" first="Anthony P." last="Nicholas">Anthony P. Nicholas</name><affiliation><mods:affiliation>Department of Neurology, University of Alabama at Birmingham and the Birmingham Veterans Administration Medical Center, Birmingham, Alabama, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-01">2007-01</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="99">99</biblScope><biblScope unit="page" to="104">104</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">62C0B2743415A52B75D6196C907163F70060A5DF</idno><idno type="DOI">10.1002/mds.21235</idno><idno type="ArticleID">MDS21235</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MPTP</term><term>Parkinson's disease</term><term>dyskinesia</term><term>levodopa</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The present study examines the motor responses of 10‐ to 12‐month‐old, male C57 mice that were either given intraperitoneal (IP) injections of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP; 30 mg/kg per day) or vehicle for 10 consecutive days, followed by IP injections of levodopa (200 mg/kg) plus carbidopa (25 mg/kg). Five days of MPTP exposure resulted in the Straub tail phenomenon and pronounced hypokinesia. However, during the next 5 days, motor activity returned to baseline, even with continued MPTP treatment. After 10 to 14 days of rest, all mice were then treated with levodopa/carbidopa twice daily for multiple, consecutive days. However, only the previously MPTP‐treated animals became hyperkinetic, as compared to levodopa‐treated control animals that were not previously exposed to MPTP. Abnormal activity included scratching, running, gnawing, and jumping movements. Hyperactivity lasted for approximately 2 hours after each levodopa injection and then returned to baseline, but the amount of hyperkinesia increased with additional days of levodopa treatment, even though the daily levodopa dose was not changed. These results demonstrate that levodopa can cause reproducible hyperactivity in mice that were previously exposed to MPTP. © 2006 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Anthony P. Nicholas MD, PhD</name><affiliations><json:string>Department of Neurology, University of Alabama at Birmingham and the Birmingham Veterans Administration Medical Center, Birmingham, Alabama, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>dyskinesia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MPTP</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item></subject><language><json:string>eng</json:string></language><abstract>The present study examines the motor responses of 10‐ to 12‐month‐old, male C57 mice that were either given intraperitoneal (IP) injections of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP; 30 mg/kg per day) or vehicle for 10 consecutive days, followed by IP injections of levodopa (200 mg/kg) plus carbidopa (25 mg/kg). Five days of MPTP exposure resulted in the Straub tail phenomenon and pronounced hypokinesia. However, during the next 5 days, motor activity returned to baseline, even with continued MPTP treatment. After 10 to 14 days of rest, all mice were then treated with levodopa/carbidopa twice daily for multiple, consecutive days. However, only the previously MPTP‐treated animals became hyperkinetic, as compared to levodopa‐treated control animals that were not previously exposed to MPTP. Abnormal activity included scratching, running, gnawing, and jumping movements. Hyperactivity lasted for approximately 2 hours after each levodopa injection and then returned to baseline, but the amount of hyperkinesia increased with additional days of levodopa treatment, even though the daily levodopa dose was not changed. These results demonstrate that levodopa can cause reproducible hyperactivity in mice that were previously exposed to MPTP. © 2006 Movement Disorder Society</abstract><qualityIndicators><score>5.945</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1292</abstractCharCount><pdfWordCount>3737</pdfWordCount><pdfCharCount>24692</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>184</abstractWordCount></qualityIndicators><title>Levodopa‐induced hyperactivity in mice treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine</title><genre><json:string>Serial article</json:string></genre><host><volume>22</volume><pages><total>6</total><last>104</last><first>99</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21235</json:string></doi><id>62C0B2743415A52B75D6196C907163F70060A5DF</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/62C0B2743415A52B75D6196C907163F70060A5DF/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/62C0B2743415A52B75D6196C907163F70060A5DF/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/62C0B2743415A52B75D6196C907163F70060A5DF/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Levodopa‐induced hyperactivity in mice treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2007</date></publicationStmt><notesStmt><note>Parkinson Association of Alabama</note><note>Research Program of the Department of Veterans Health Administration</note><note>Strain Family Foundation</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Levodopa‐induced hyperactivity in mice treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine</title><author><persName><forename type="first">Anthony P.</forename><surname>Nicholas</surname><roleName type="degree">MD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Sparks Center 360‐G2, Department of Neurology, 1530 3rd Avenue South, University of Alabama at Birmingham, Birmingham, AL 35294‐0017</p></note><affiliation>Department of Neurology, University of Alabama at Birmingham and the Birmingham Veterans Administration Medical Center, Birmingham, Alabama, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-01"></date><biblScope unit="vol">22</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="99">99</biblScope><biblScope unit="page" to="104">104</biblScope></imprint></monogr><idno type="istex">62C0B2743415A52B75D6196C907163F70060A5DF</idno><idno type="DOI">10.1002/mds.21235</idno><idno type="ArticleID">MDS21235</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The present study examines the motor responses of 10‐ to 12‐month‐old, male C57 mice that were either given intraperitoneal (IP) injections of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP; 30 mg/kg per day) or vehicle for 10 consecutive days, followed by IP injections of levodopa (200 mg/kg) plus carbidopa (25 mg/kg). Five days of MPTP exposure resulted in the Straub tail phenomenon and pronounced hypokinesia. However, during the next 5 days, motor activity returned to baseline, even with continued MPTP treatment. After 10 to 14 days of rest, all mice were then treated with levodopa/carbidopa twice daily for multiple, consecutive days. However, only the previously MPTP‐treated animals became hyperkinetic, as compared to levodopa‐treated control animals that were not previously exposed to MPTP. Abnormal activity included scratching, running, gnawing, and jumping movements. Hyperactivity lasted for approximately 2 hours after each levodopa injection and then returned to baseline, but the amount of hyperkinesia increased with additional days of levodopa treatment, even though the daily levodopa dose was not changed. These results demonstrate that levodopa can cause reproducible hyperactivity in mice that were previously exposed to MPTP. © 2006 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>dyskinesia</term></item><item><term>levodopa</term></item><item><term>MPTP</term></item><item><term>Parkinson's disease</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-03-27">Received</change><change when="2006-08-15">Registration</change><change when="2007-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/62C0B2743415A52B75D6196C907163F70060A5DF/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/mds.v22:1</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="2007-01">January 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="140" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21235</doi><idGroup><id type="unit" value="MDS21235"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2006 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2006-03-27"></event><event type="manuscriptRevised" date="2006-08-14"></event><event type="manuscriptAccepted" date="2006-08-15"></event><event type="firstOnline" date="2006-11-28"></event><event type="publishedOnlineFinalForm" date="2007-01-22"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2006-11-28"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">99</numbering><numbering type="pageLast">104</numbering></numberingGroup><correspondenceTo>Sparks Center 360‐G2, Department of Neurology, 1530 3rd Avenue South, University of Alabama at Birmingham, Birmingham, AL 35294‐0017</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21235.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="54"></count><count type="wordTotal" number="4163"></count></countGroup><titleGroup><title type="main" xml:lang="en">Levodopa‐induced hyperactivity in mice treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine</title><title type="short" xml:lang="en">Levodopa‐Induced Hyperactivity in MPTP Mice</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Anthony P.</givenNames><familyName>Nicholas</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>nicholas@uab.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Alabama at Birmingham and the Birmingham Veterans Administration Medical Center, Birmingham, Alabama, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">dyskinesia</keyword><keyword xml:id="kwd2">levodopa</keyword><keyword xml:id="kwd3">MPTP</keyword><keyword xml:id="kwd4">Parkinson's disease</keyword></keywordGroup><fundingInfo><fundingAgency>Parkinson Association of Alabama</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Research Program of the Department of Veterans Health Administration</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Strain Family Foundation</fundingAgency></fundingInfo><supportingInformation><p> This article includes Supplementary Video, available online at <url href="http://www.interscience.wiley.com/jpages/0885-3185/suppmat"> http://www.interscience.wiley.com/jpages/0885‐3185/suppmat </url></p><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds21235:jws-mds"></mediaResource><caption> Segment 1 . This is an experiment comparing two aged male mice: one receiving MPTP in ethanol for 10 days and the other receiving vehicle injections. The video is taken on day 4 of vehicle versus MPTP treatment. The animal that is shown first is the vehicle‐injected mouse and it is moving normally. However, the other mouse pictured is the MPTP‐treated mouse. It is hypokinetic and exhibits the Straub tail phenomenon. Later the two animals are pictured together. The vehicle‐injected mouse (left) moves normally, while the MPTP‐treated mouse (right) is minimally interactive. Notice how the normal mouse will explore the environment, while the MPTP‐treated mouse moves minimally. Within the first week, the MPTP‐treated mouse will recover its motor function and become indistinguishable from the vehicle‐injected mouse. </caption></supportingInfoItem><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds21235:jws-mds"></mediaResource><caption> Segment 2 . These two animals are the same mice that were recorded previously in the first video segment. It is 2 weeks later, and both mice have received 3 days of carbidopa/ L ‐dopa b.i.d. The mouse on the left previously received MPTP, while the animal on the right was the vehicle‐injected control mouse. The previously MPTP‐treated mouse has developed extreme hyperkinesis in response toL ‐dopa, while the control mouse acts normally. Levodopa‐induced hyperkinesis in this previously MPTP‐treated mouse is quite impressive, with panting and almost constant movement. </caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The present study examines the motor responses of 10‐ to 12‐month‐old, male C57 mice that were either given intraperitoneal (IP) injections of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP; 30 mg/kg per day) or vehicle for 10 consecutive days, followed by IP injections of levodopa (200 mg/kg) plus carbidopa (25 mg/kg). Five days of MPTP exposure resulted in the Straub tail phenomenon and pronounced hypokinesia. However, during the next 5 days, motor activity returned to baseline, even with continued MPTP treatment. After 10 to 14 days of rest, all mice were then treated with levodopa/carbidopa twice daily for multiple, consecutive days. However, only the previously MPTP‐treated animals became hyperkinetic, as compared to levodopa‐treated control animals that were not previously exposed to MPTP. Abnormal activity included scratching, running, gnawing, and jumping movements. Hyperactivity lasted for approximately 2 hours after each levodopa injection and then returned to baseline, but the amount of hyperkinesia increased with additional days of levodopa treatment, even though the daily levodopa dose was not changed. These results demonstrate that levodopa can cause reproducible hyperactivity in mice that were previously exposed to MPTP. © 2006 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Levodopa‐induced hyperactivity in mice treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Levodopa‐Induced Hyperactivity in MPTP Mice</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Levodopa‐induced hyperactivity in mice treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine</title></titleInfo><name type="personal"><namePart type="given">Anthony P.</namePart><namePart type="family">Nicholas</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, University of Alabama at Birmingham and the Birmingham Veterans Administration Medical Center, Birmingham, Alabama, USA</affiliation><description>Correspondence: Sparks Center 360‐G2, Department of Neurology, 1530 3rd Avenue South, University of Alabama at Birmingham, Birmingham, AL 35294‐0017</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-01</dateIssued><dateCaptured encoding="w3cdtf">2006-03-27</dateCaptured><dateValid encoding="w3cdtf">2006-08-15</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="references">54</extent><extent unit="words">4163</extent></physicalDescription><abstract lang="en">The present study examines the motor responses of 10‐ to 12‐month‐old, male C57 mice that were either given intraperitoneal (IP) injections of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP; 30 mg/kg per day) or vehicle for 10 consecutive days, followed by IP injections of levodopa (200 mg/kg) plus carbidopa (25 mg/kg). Five days of MPTP exposure resulted in the Straub tail phenomenon and pronounced hypokinesia. However, during the next 5 days, motor activity returned to baseline, even with continued MPTP treatment. After 10 to 14 days of rest, all mice were then treated with levodopa/carbidopa twice daily for multiple, consecutive days. However, only the previously MPTP‐treated animals became hyperkinetic, as compared to levodopa‐treated control animals that were not previously exposed to MPTP. Abnormal activity included scratching, running, gnawing, and jumping movements. Hyperactivity lasted for approximately 2 hours after each levodopa injection and then returned to baseline, but the amount of hyperkinesia increased with additional days of levodopa treatment, even though the daily levodopa dose was not changed. These results demonstrate that levodopa can cause reproducible hyperactivity in mice that were previously exposed to MPTP. © 2006 Movement Disorder Society</abstract><note type="funding">Parkinson Association of Alabama</note><note type="funding">Research Program of the Department of Veterans Health Administration</note><note type="funding">Strain Family Foundation</note><subject lang="en"><genre>Keywords</genre><topic>dyskinesia</topic><topic>levodopa</topic><topic>MPTP</topic><topic>Parkinson's disease</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><note type="content"> This article includes Supplementary Video, available online at http://www.interscience.wiley.com/jpages/0885‐3185/suppmatSupporting Info Item: Segment 1 . This is an experiment comparing two aged male mice: one receiving MPTP in ethanol for 10 days and the other receiving vehicle injections. The video is taken on day 4 of vehicle versus MPTP treatment. The animal that is shown first is the vehicle‐injected mouse and it is moving normally. However, the other mouse pictured is the MPTP‐treated mouse. It is hypokinetic and exhibits the Straub tail phenomenon. Later the two animals are pictured together. The vehicle‐injected mouse (left) moves normally, while the MPTP‐treated mouse (right) is minimally interactive. Notice how the normal mouse will explore the environment, while the MPTP‐treated mouse moves minimally. Within the first week, the MPTP‐treated mouse will recover its motor function and become indistinguishable from the vehicle‐injected mouse. - Segment 2 . These two animals are the same mice that were recorded previously in the first video segment. It is 2 weeks later, and both mice have received 3 days of carbidopa/ L ‐dopa b.i.d. The mouse on the left previously received MPTP, while the animal on the right was the vehicle‐injected control mouse. The previously MPTP‐treated mouse has developed extreme hyperkinesis in response toL ‐dopa, while the control mouse acts normally. Levodopa‐induced hyperkinesis in this previously MPTP‐treated mouse is quite impressive, with panting and almost constant movement. - </note><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>99</start><end>104</end><total>6</total></extent></part></relatedItem><identifier type="istex">62C0B2743415A52B75D6196C907163F70060A5DF</identifier><identifier type="DOI">10.1002/mds.21235</identifier><identifier type="ArticleID">MDS21235</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2006 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001861 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001861 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:62C0B2743415A52B75D6196C907163F70060A5DF
|texte= Levodopa‐induced hyperactivity in mice treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine
}}
| This area was generated with Dilib version V0.6.23. |  |